We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+13.47%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.57B
AUM Growth
+$553M
Cap. Flow
+$561M
Cap. Flow %
15.73%
Top 10 Hldgs %
49.57%
Holding
170
New
38
Increased
32
Reduced
29
Closed
33

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$104M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$79.7M
3
ASND icon
Ascendis Pharma A/S
ASND
+$55.2M
4
YARW
Yarrow Bioscience
YARW
+$54M
5
FOLD
Amicus Therapeutics
FOLD
+$32.5M

Top Sells

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$58.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$32.9M
3
ISRG icon
Intuitive Surgical
ISRG
+$25.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$24.2M
5
ZBH icon
Zimmer Biomet
ZBH
+$24.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.46%
2 Consumer Staples 0.67%
3 Consumer Discretionary 0.06%
4 Industrials 0.02%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCLI
101
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.26M 0.04%
26,667
– –
VIVE
102
DELISTED
VIVEVE MED INC
VIVE
$1.23M 0.03%
+335
New +$1.46M
PGNX
103
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$1.21M 0.03%
162,500
+100,650
+163% +$669K
VRNA
104
DELISTED
Verona Pharma
VRNA
$1.12M 0.03%
56,168
-143,832
-72% -$2.08M
DVAX
105
DELISTED
Dynavax Technologies
DVAX
$1.11M 0.03%
+55,713
New +$962K
SNDA icon
106
Sonida Senior Living
SNDA
$1.97B
$1.08M 0.03%
6,678
-38,667
-85% -$6.87M
ONC
107
BeOne Medicines Ltd
ONC
$42.6B
$958K 0.03%
5,700
– –
MRTX
108
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$893K 0.03%
29,091
– –
TARA icon
109
Protara Therapeutics
TARA
$235M
$835K 0.02%
8,353
– –
ADYX
110
DELISTED
Adynxx Inc
ADYX
$821K 0.02%
70,566
– –
ESPR
111
DELISTED
Esperion Therapeutics
ESPR
$779K 0.02%
10,769
– –
RACE icon
112
Ferrari
RACE
$74.1B
$747K 0.02%
6,200
– –
ENTA icon
113
Enanta Pharmaceuticals
ENTA
$410M
$739K 0.02%
+9,132
New +$703K
GRDX
114
GridAI Technologies Corp
GRDX
$28.7M
$714K 0.02%
2
– –
ARRY
115
DELISTED
Array Biopharma Inc
ARRY
$655K 0.02%
+40,133
New +$643K
NKTR icon
116
Nektar Therapeutics
NKTR
$2.56B
$644K 0.02%
+404
New +$520K
VRAY
117
DELISTED
ViewRay, Inc.
VRAY
$643K 0.02%
100,000
+50,000
+100% +$417K
CUTR
118
DELISTED
Cutera, Inc.
CUTR
$602K 0.02%
11,981
– –
GERN icon
119
PUT
Geron
GERN
$996M
$600K 0.02%
+600,000
New +$1.62M
TRHC
120
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
$569K 0.02%
+14,663
New +$514K
SGMO
121
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$475K 0.01%
+25,000
New +$534K
ADVM
122
DELISTED
Adverum Biotechnologies
ADVM
$469K 0.01%
+8,085
New +$503K
IMUX icon
123
PUT
Immunic
IMUX
$224M
$454K 0.01%
+375
New +$861K
SENS icon
124
Senseonics Holdings Inc
SENS
$503M
$345K 0.01%
5,750
– –
REGN icon
125
CALL
Regeneron Pharmaceuticals
REGN
$85.8B
$335K 0.01%
+50,000
New +$17.4M
3 4
5
6 7

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q1 2018 Portfolio in Review

As of Q1 2018, Perceptive Advisors held 170 positions worth $3.57B, up 18% from $3.02B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors deployed $561M of net new capital in Q1 2018, opening 38 new positions and adding to 32 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was AnaptysBio, an estimated $58.5M trimmed.

  • Perceptive Advisors's largest Q1 2018 buy was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.
  • Perceptive Advisors added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018, an estimated $79.7M increase.
  • Perceptive Advisors's biggest Q1 2018 reduction was AnaptysBio, cutting an estimated $58.5M.
  • Perceptive Advisors fully exited Zimmer Biomet in Q1 2018, selling an estimated $24.1M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $3.57B portfolio in Q1 2018.
  • Perceptive Advisors opened 38 new positions and closed 33 in Q1 2018.
  • Perceptive Advisors's portfolio value rose 18% quarter-over-quarter to $3.57B.

Based on Perceptive Advisors's 13F filing for Q1 2018, filed 15 May 2018.